Training in a CGMP environment is very important as it is a very important requirement of the regulations. Training is simply one of the means to fill the gaps of performance between the actual results and the expected results.
VIP Call Girls Tirunelveli Aaradhya 8250192130 Independent Escort Service Tir...
Training in cGMP Environment for Begninners
1. This presentation is compiled by “ Drug Regulations” a
non profit organization which provides free online
resource to the Pharmaceutical Professional.
Visit http://www.drugregulations.org for latest
information from the world of Pharmaceuticals.
11/3/2014 1
2. This presentation is compiled from freely
available resources like the websites of FDA,
EMA, WHO.
“Drug Regulations” is a non profit
organization which provides free online
resource to the Pharmaceutical Professional.
Visit http://www.drugregulations.org for
latest information from the world of
Pharmaceuticals.
11/3/2014 2
Drug Regulations : Online
Resource for Latest Information
3. Regulations Governing Training
Food and Drug Administration
European Medicines Agency
World Health Organization
11/3/2014 3
Drug Regulations : Online
Resource for Latest Information
4. Training in current good manufacturing
practice shall be conducted by qualified
individuals on a continuing basis and with
sufficient frequency to assure that employees
remain familiar with CGMP requirements
applicable to them.
11/3/2014 4
Drug Regulations : Online
Resource for Latest Information
5. ◦ Each person responsible for supervising the
manufacture, processing, packing, or holding of a
drug product shall have the education, training,
and experience, or any combination thereof, to
perform assigned functions in such a manner as
to provide assurance that the drug product has
the safety, identity, strength, quality, and purity
that it purports or is represented to possess.
11/3/2014 5
Drug Regulations : Online
Resource for Latest Information
6. ◦ There shall be an adequate number of qualified
personnel to perform and supervise the
manufacture, processing, packing, or holding of
each drug product.
11/3/2014 6
Drug Regulations : Online
Resource for Latest Information
7. ◦ The personnel shall receive initial and ongoing
training, the effectiveness of which shall be verified,
covering in particular the theory and application of the
concept of quality assurance and good manufacturing
practice, and, where appropriate, the particular
requirements for the manufacture of investigational
medicinal products.
11/3/2014 7
Drug Regulations : Online
Resource for Latest Information
8. ◦ 2.8 The manufacturer should provide training for
all the personnel whose duties take them into
production areas or into control laboratories
(including the technical, maintenance and
cleaning personnel), and for other personnel
whose activities could affect the quality of the
product.
11/3/2014 8
Drug Regulations : Online
Resource for Latest Information
9. ◦ 2.9 Besides the basic training on the theory and practice of
Good Manufacturing Practice, newly recruited personnel
should receive training appropriate to the duties assigned to
them. Continuing training should also be given, and its
practical effectiveness should be periodically assessed.
Training programmes should be available, approved by either
the head of Production or the head of Quality Control, as
appropriate. Training records should be kept.
11/3/2014 9
Drug Regulations : Online
Resource for Latest Information
10. 2.10 Personnel working in areas where contamination is a
hazard, e.g. clean areas or areas where highly active, toxic,
infectious or sensitising materials are handled, should be
given specific training.
11/3/2014 10
Drug Regulations : Online
Resource for Latest Information
11. 2.12 The concept of Quality Assurance and all the
measures capable of improving its understanding and
implementation should be fully discussed during the
training sessions.
11/3/2014 11
Drug Regulations : Online
Resource for Latest Information
12. 10.1 The manufacturer should provide training in
accordance with a written programme for all
personnel whose duties take them into
manufacturing areas or into control laboratories
(including the technical, maintenance and cleaning
personnel) and for other personnel as required.
11/3/2014 12
Drug Regulations : Online
Resource for Latest Information
13. 10.2 Besides basic training on the theory and practice
of GMP, newly recruited personnel should receive
training appropriate to the duties assigned to them.
Continuing training should also be given, and its
practical effectiveness periodically assessed.
Approved training programmes should be available.
Training records should be kept.
11/3/2014 13
Drug Regulations : Online
Resource for Latest Information
14. 10.3 Personnel working in areas where contamination
is a hazard, e.g. clean areas or areas where highly
active, toxic, infectious or sensitizing materials are
handled, should be given specific training.
11/3/2014 14
Drug Regulations : Online
Resource for Latest Information
15. 10.4 The concept of QA and all the measures which
aid its understanding and implementation should be
fully discussed during the training sessions.
11/3/2014 15
Drug Regulations : Online
Resource for Latest Information
16. 10.5 Visitors or untrained personnel should
preferably not be taken into the production and QC
areas. If this is unavoidable, they should be given
relevant information in advance (particularly about
personal hygiene) and the prescribed protective
clothing. They should be closely supervised.
11/3/2014 16
Drug Regulations : Online
Resource for Latest Information
17. 10.6 Consultant and contract staff should be
qualified for the services they provide. Evidence of
this should be included in the training records.
11/3/2014 17
Drug Regulations : Online
Resource for Latest Information
18. All personnel should be aware of GMP
Production
Control Laboratories
Others whose activities could affect Quality of the
products
Including Technical , Maintenance & cleaning
personnel
11/3/2014 18
Drug Regulations : Online
Resource for Latest Information
19. All personnel Must receive training in GMP:
Initial
Continuing
Specialized
Including Hygiene Standards
11/3/2014 19
Drug Regulations : Online
Resource for Latest Information
20. Written & approved program
On theory and practice of GMP and their duties
Training records should be kept
Practical effectiveness checked
Training before undertaking any new task
11/3/2014 20
Drug Regulations : Online
Resource for Latest Information
21. ◦ Specific training for staff in special areas, e.g.
Where contamination is a hazard
Clean areas, Aseptic Processes
Areas where highly active, toxic, infectious,
sensitizing materials are handled
◦ The concept of QA should be fully discussed during
training to facilitate proper understanding to ensure
its implementation
11/3/2014 21
Drug Regulations : Online
Resource for Latest Information
22. Each person
Quality , Manufacturing, Engineering , Warehouse, House
keeping, Contractors
Area of work + cGMP
Experts in area of operation + cGMP by qualified
individuals
Continuing basis , Sufficient frequency
Approved training program
By Quality , By Production
11/3/2014 22
Drug Regulations : Online
Resource for Latest Information
23. Practical effectiveness checked
Observing on the job , Written Questioners , Oral
Interviews
Periodically assessed
Specialized Training
Sterile , OOS , Potent substances
Quality Assurance to be discussed in training
Records maintained
11/3/2014 23
Drug Regulations : Online
Resource for Latest Information
24. 24
Assessment Stage
Organizational
Needs
Task Needs
Development of
Training
Objectives
Development of
Criteria for
Evaluation
Training Stage
Design & Select
Procedures
Train
Evaluation Stage
Measure Training
Results
Compare Results
to Criteria
25. 25
Assessing training needs
Preparing training plan
Specifying training objectives
Designing training program(s)
Selecting instructional methods
Completing the training plan
Implementing the training program
Evaluating the training
Planning future training
Drug Regulations : Online
Resource for Latest Information
26. 26
Participation: Involve trainees, learn by doing
Repetition: Repeat ideas & concepts to help people learn
Relevance: Learn better when material is meaningful
Transference: To real world using simulations
Feedback: Adjust training methods to audience.
Drug Regulations : Online
Resource for Latest Information
27. 27
Is Training Crucial ?
Drug Regulations : Online
Resource for Latest Information
29. Import Alerts –
2 plants
2 Warning Letters
29
Performance/Results
No Import Alert
No Warning Letter
No 483”s
Time
Expected Results
Actual Results
Gap
5 % Productivity Increase
7 % Decrease in Productivity
483’s – 20
observation
10 % Cost Reduction
10 % Cost Increase
High Stock Price
Stock Price Crashes
Exports : $ 150 million
Loss of Export Revenue
30. 30
Training is simply one of the means to fill the gaps of
performance between the actual results and the expected
results.
This GAP can be separated into 3 main themes
1. Attitude
2. Skills
3. Knowledge
31. 31
1. Attitude
2. Skills
3. Knowledge
• Easy
• Moderately difficult
• Most difficult
Drug Regulations : Online
Resource for Latest Information
32. 32
1. Attitude
Jung's definition of attitude is a "readiness of the
psyche to act or react in a certain way"
33. 33
2. Skills
Skill refers to
The ability of using information and applying it in a
context.
Practical application of knowledge
Practical exposure and can also be in-born
Skill is required to master a field of study
34. 34
3. Knowledge
Knowledge refers to theoretical information acquired
about any subject
Knowledge can be learned
Knowledge is also required to master a field of study
36. 11/3/2014 36
Rank.
12
13
Ref No Freq
2012
2013
Description
1
1
21 CFR
211.22 (d)
169
155
The responsibilities and procedures
applicable to the quality control unit are not
[in writing] [fully followed].
2
2
21 CFR
211.192
119
131
There is a failure to thoroughly review [any
unexplained discrepancy] [the failure of a
batch or any of its components to meet any
of its specifications] whether or not the
batch has been already distributed.
37. 11/3/2014 37
Rank
12
13
Ref No Freq
2012
2013
Description
6 5 21 CFR
211.67(b)
73
77
Written procedures not
established/followed for cleaning &
main of equip.
7
12
21 CFR
211.68(a)
69
56
Calibration/Inspection/Checking not
done
8
7
21 CFR
211.67(a)
65
71
Cleaning / Sanitizing / Maintenance not
done
9
11
21 CFR
211.100(b)
64
59
Written production and process control
procedures are not followed .
38. 1. Warning Letter to a Contract Manufacturer.
“An operator performing critical aseptic operations with
exposed skin at the forehead, posing an unreasonable
risk of the product becoming contaminated.
Operators moving very quickly in the aseptic area, which
may create unacceptable turbulence in the area, and
disrupt the unidirectional airflow.
Operators leaning halfway in and out of the class 100
area while performing interventions over opened bottles.”
11/3/2014 38
39. 2. Warning letter issued to a Contract Manufacturer.
◦ “ Your firm failed to document in the batch record that
the sterilization cycle for (b)(4) Solution, lot (b)(4) was
aborted due to a failure to reach the (b)(4) set point
temperature during production.
◦ …….. The sterilization cycle deviation was not
documented in batch records or your firm’s incident
logs. Your firm also lacked any documentation, such
as a printout, of the (b)(4) time and temperatures for
the aborted load. ”
11/3/2014 39
40. 3. Medium Size MNC in India
◦ Surfaces are not always sanitized prior to use….the investigator
observed an operator bringing the out-feed vial transfer belt from
outside the primary HEPA area and re-attaching it to the line without
sanitizing the belt.
◦ Aseptic manufacturing interventions are not performed in a manner to
protect sterile drug products from contamination…the investigator
observed at least two instances in which operators performed
interventions requiring them to reach over unstoppered vials. In both
cases, the exposed vials were not removed and line clearance was not
performed.
11/3/2014 40
41. 5. Warning Letter to a Large Indian Company
◦ “The FDA investigator observed a microbiological
plate that contained one (1) large colony forming
unit (CFU) of mold. However, your firm’s
laboratory documentation reported 0 CFU for the
same microbiological plate”.
11/3/2014 41
42. 6. Warning Letter to a Large Indian Company
◦ “Your microbiologists reported microbiological
plates as “nil” while each plate contained one (1)
colony forming unit (CFU)”.
11/3/2014 42
43. 7. Warning Letter to a Large Indian Company
◦ “Your firm repeatedly delayed, denied, limited an
inspection or refused to permit the FDA
inspection.
◦ “The FDA investigators found unofficial batch
records for approximately 75 batches of
injectable finished drug products torn in half in a
waste area”.
11/3/2014 43
44. 8. Warning Letter to a Large Indian Company
◦ “It appears that QC analysts attempted to mask
the practice of performing sample “trial”
injections by labeling them as standards rather
than by the actual batch numbers or other
identifying information”.
11/3/2014 44
45. 9. Warning Letter to a Medium Sized Indian
Company
◦ “Your firm repeated these assays, and selectively
reported only the passing retest values in the
final assay results, then disregarded the initial
OOS data without conducting investigations”
11/3/2014 45
46. 10.“Warning Letter to a Medium size MNC in India
◦ “We observed and documented practices during the
inspection that kept some samples, data and results
outside of the local systems for assessing quality.
◦ This raises serious concerns regarding the integrity
and reliability of the data generated at your plant.
◦ During the inspection your firm also repeatedly
delayed, denied, limited or refused to provide
information to the FDA investigators”.
11/3/2014 46
47. ◦ FDA form 483 issued to a medium sized Indian
company
◦ “Established laboratory controls are not followed and
data is not recorded at the time of performance:
Sample and standard analytical weight print outs are not
printed at the time of weighing.
Analytical balance clocks are set back in order to create
falsified weight printouts that appear to be printed at the
time of sample weighing.
Drug product test method validation data is falsified”
11/3/2014 47
48. ◦ EMA GMP-Non-Compliance Statements
Companies from India and China are by far the most
represented.
What is really freighting is the number of NCR’s which
cite data falsification in their report.
Out of the 34 Non Compliance reports for the Indian
Companies 50 % cite Data Falsification as a Critical issue.
11/3/2014 48
49. 49
Regulatory Requirements
Maintains qualified products / services
Achieves high performance /service / quality standards
Provides information to new comers
Refreshes memory of old employees
Achieves learning about new requirements , standards , technology,
products , service delivery
Reduces mistakes - minimizing costs
Opportunity for staff to give feedback / suggest improvements
Improves communication & relationships - better teamwork
Drug Regulations : Online
Resource for Latest Information
50. This presentation is compiled from freely
available resources like the websites of FDA,
EMA, WHO.
“Drug Regulations” is a non profit
organization which provides free online
resource to the Pharmaceutical Professional.
Visit http://www.drugregulations.org for
latest information from the world of
Pharmaceuticals.
11/3/2014 50
Drug Regulations : Online
Resource for Latest Information